Interaction between Immunotherapy and Antiangiogenic Therapy for Cancer

Although immunotherapy has led to durable responses in diverse cancers, unfortunately, there has been limited efficacy and clinical response rates due to primary or acquired resistance to immunotherapy. To maximize the potential of immunotherapy, combination therapy with antiangiogenic drugs seems t...

Descripción completa

Detalles Bibliográficos
Autores principales: Furukawa, Koichi, Nagano, Tatsuya, Tachihara, Motoko, Yamamoto, Masatsugu, Nishimura, Yoshihiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7504110/
https://www.ncbi.nlm.nih.gov/pubmed/32859106
http://dx.doi.org/10.3390/molecules25173900
_version_ 1783584548710252544
author Furukawa, Koichi
Nagano, Tatsuya
Tachihara, Motoko
Yamamoto, Masatsugu
Nishimura, Yoshihiro
author_facet Furukawa, Koichi
Nagano, Tatsuya
Tachihara, Motoko
Yamamoto, Masatsugu
Nishimura, Yoshihiro
author_sort Furukawa, Koichi
collection PubMed
description Although immunotherapy has led to durable responses in diverse cancers, unfortunately, there has been limited efficacy and clinical response rates due to primary or acquired resistance to immunotherapy. To maximize the potential of immunotherapy, combination therapy with antiangiogenic drugs seems to be promising. Some phase III trials showed superiority for survival with the combination of immunotherapy and antiangiogenic therapy. In this study, we describe a synergistic mechanism of immunotherapy and antiangiogenic therapy and summarize current clinical trials of these combinations.
format Online
Article
Text
id pubmed-7504110
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-75041102020-09-24 Interaction between Immunotherapy and Antiangiogenic Therapy for Cancer Furukawa, Koichi Nagano, Tatsuya Tachihara, Motoko Yamamoto, Masatsugu Nishimura, Yoshihiro Molecules Review Although immunotherapy has led to durable responses in diverse cancers, unfortunately, there has been limited efficacy and clinical response rates due to primary or acquired resistance to immunotherapy. To maximize the potential of immunotherapy, combination therapy with antiangiogenic drugs seems to be promising. Some phase III trials showed superiority for survival with the combination of immunotherapy and antiangiogenic therapy. In this study, we describe a synergistic mechanism of immunotherapy and antiangiogenic therapy and summarize current clinical trials of these combinations. MDPI 2020-08-26 /pmc/articles/PMC7504110/ /pubmed/32859106 http://dx.doi.org/10.3390/molecules25173900 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Furukawa, Koichi
Nagano, Tatsuya
Tachihara, Motoko
Yamamoto, Masatsugu
Nishimura, Yoshihiro
Interaction between Immunotherapy and Antiangiogenic Therapy for Cancer
title Interaction between Immunotherapy and Antiangiogenic Therapy for Cancer
title_full Interaction between Immunotherapy and Antiangiogenic Therapy for Cancer
title_fullStr Interaction between Immunotherapy and Antiangiogenic Therapy for Cancer
title_full_unstemmed Interaction between Immunotherapy and Antiangiogenic Therapy for Cancer
title_short Interaction between Immunotherapy and Antiangiogenic Therapy for Cancer
title_sort interaction between immunotherapy and antiangiogenic therapy for cancer
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7504110/
https://www.ncbi.nlm.nih.gov/pubmed/32859106
http://dx.doi.org/10.3390/molecules25173900
work_keys_str_mv AT furukawakoichi interactionbetweenimmunotherapyandantiangiogenictherapyforcancer
AT naganotatsuya interactionbetweenimmunotherapyandantiangiogenictherapyforcancer
AT tachiharamotoko interactionbetweenimmunotherapyandantiangiogenictherapyforcancer
AT yamamotomasatsugu interactionbetweenimmunotherapyandantiangiogenictherapyforcancer
AT nishimurayoshihiro interactionbetweenimmunotherapyandantiangiogenictherapyforcancer

Ejemplares similares